This tiered approach allows investors to engage at the level they’re most comfortable with, sparking their interest with a ...

The team from the University of Bath in the UK, Poland's Kozminski Academy and Lund University in Sweden have concluded that ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible combination with Hookipa, an Austrian biotech that ...

Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Although Boston, San Francisco, and San Diego are the top three life sciences markets in the US, they are burdened by an oversupply of lab buildings that offer lab space. There is an undersupply of ...

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid ...